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Background: Increasing rates of resistant and multidrug-resistant (MDR) P. aeruginosa in hospitalized patients
constitute a major public health threat. We present a systematic review of the clinical and economic impact of this
resistant pathogen.
Methods: Studies indexed in MEDLINE and Cochrane databases between January 2000-February 2013, and reported
all-cause mortality, length of stay, hospital costs, readmission, or recurrence in at least 20 hospitalized patients with
laboratory confirmed resistant P. aeruginosa infection were included. We accepted individual study definitions of
MDR, and assessed study methodological quality.
Results: The most common definition of MDR was resistance to more than one agent in three or more
categories of antibiotics. Twenty-three studies (7,881 patients with susceptible P. aeruginosa, 1,653 with resistant
P. aeruginosa, 559 with MDR P. aeruginosa, 387 non-infected patients without P. aeruginosa) were analyzed. A
random effects model meta-analysis was feasible for the endpoint of all-cause in-hospital mortality. All-cause
mortality was 34% (95% confidence interval (CI) 27% – 41%) in patients with any resistant P. aeruginosa compared
to 22% (95% CI 14% – 29%) with susceptible P. aeruginosa. The meta-analysis demonstrated a > 2-fold increased
risk of mortality with MDR P. aeruginosa (relative risk (RR) 2.34, 95% CI 1.53 – 3.57) and a 24% increased risk with
resistant P. aeruginosa (RR 1.24, 95% CI 1.11 – 1.38), compared to susceptible P. aeruginosa. An adjusted meta-analysis of
data from seven studies demonstrated a statistically non-significant increased risk of mortality in patients with any
resistant P. aeruginosa (adjusted RR 1.24, 95% CI 0.98 – 1.57). All three studies that reported infection-related mortality
found a statistically significantly increased risk in patients with MDR P. aeruginosa compared to those with susceptible
P. aeruginosa. Across studies, hospital length of stay (LOS) was higher in patients with resistant and MDR P. aeruginosa
infections, compared to susceptible P. aeruginosa and control patients. Limitations included heterogeneity in MDR
definition, restriction to nosocomial infections, and potential confounding in analyses.
Conclusions: Hospitalized patients with resistant and MDR P. aeruginosa infections appear to have increased all-cause
mortality and LOS. The negative clinical and economic impact of these pathogens warrants in-depth evaluation of
optimal infection prevention and stewardship strategies.
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Pseudomonas aeruginosa is a frequent causative patho-
gen in healthcare associated infections [1]. P. aeruginosa
is the most common Gram-negative pathogen causing
nosocomial pneumonia in the United States, and it is
frequently implicated in hospital-acquired urinary tract
and bloodstream infections [2-4]. In a point prevalence
study conducted in Western European ICUs, P. aeruginosa
was one of the most common organisms, constituting
nearly a third (29%) of all Gram-negative isolates, and was
present in 17% of all positive cultures [5]. The Infectious
Disease Society of America includes P. aeruginosa in its list
of ‘ESKAPE’ pathogens that pose the greatest public health
threat due to a combination of increasing prevalence and
ineffectiveness of existing antibacterial agents [6].
Rates of antibiotic resistant Gram-negative infections con-
tinue to rise worldwide, and effective therapeutic options
against these infections are severely limited [7-9]. Each year
in Europe, approximately 400,000 patients with hospital-
acquired infections present with a resistant strain [10]. Re-
sistance is a particular problem with P. aeruginosa, because
of the low permeability of its cell wall [11,12] and its ability
to acquire and express multiple resistance mechanismsTable 1 Summary of data on rates of resistant Pseudomonas a
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Levofloxacin
Ceftazidime
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Piperacillin /
Souli et al. (2008), European Center for
Disease Prevention and Control (2013)
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De Francesco et al. (2013) Italy Tertiary MDR P. aeru
antibiotics) i
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Gales et al. (2001) South
America
Tertiary MDR resistan
Raja et al. (2001) Malaysia Tertiary MDR resistanincluding porin deletions and overexpression of efflux
pumps [13-17].
While the prevalence of P. aeruginosa in the last two
decades has remained stable, the prevalence of resistant
strains has increased dramatically (Table 1) [18-26]. Resist-
ant P. aeruginosa infections are associated with high mor-
tality, morbidity, and increased resource utilization and
costs [27-33]. Further, the acquisition of resistance during
anti-pseudomonal therapy among initially susceptible iso-
lates and the emergence of MDR isolates make treatment
even more challenging [34]. The high prevalence of resist-
ance and resultant limited treatment options leads to
inappropriate empiric therapy [24,35], which is associated
with poor clinical and economic outcomes [36-42].
Several studies have examined the impact of resistant
Gram-negative bacilli generally and MDR P. aeruginosa
specifically, but there has not been an in-depth, comparative
analysis of the contemporary literature reporting on mortal-
ity, morbidity and costs associated with resistant versus
susceptible infection. This report is a systematic review of
the clinical and economic consequences of resistant and
MDR P. aeruginosa compared to susceptible P. aeruginosa
and control patients without P. aeruginosa infections. Weeruginosa
istance Ref.
sistance = 15% [18]
esistance = 9%
on cephalosporin resistance = 20%
ginosa (defined as resistance to at least three of the following
mipenem, ceftazidime, ciprofloxacin, and tobramycin) increased
993 to 14% in 2002
[19]
resistance = 11.4% [20]
sistance = 21.9%
resistance = 15.4%
resistance = 26.0%
resistance = 15.2%
resistance = 10.1%
tazobactam resistance = 14.7%
resistance = > 25% [21,22]
ginosa (defined as resistance to 5 commonly prescribed
ncreased from 2.1% in 2007 to 4.1% in 2010
[23]
resistance = 37% [24]
esistance = 22%
sistance = 23%
lone resistance = 24%
side resistance = 18%
ce = 8.2% [25]
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Table 2 Description of studies included in systematic review
Study (Year) Study Design Setting/
location
Source of
Infection
Definition of Resistance / Controls Study Population Patients
(n)
Ref.
Akhabue et al.
(2011)
Retrospective
Observational
Tertiary;
USA
Genitourinary,
respiratory
wound, blood,
tissue
Culture positive results for cefepime susceptible or resistant P. aeruginosa Cefepime resistant P. aeruginosa 213 [61]
Susceptible P. aeruginosa 2316
Brooklyn Antibiotic
Resistance Task
Force (2002)
Retrospective
Observational
Tertiary;
USA
Genitourinary,
respiratory,
wound
Culture positive results for carbapenem susceptible or resistant P. aeruginosa Susceptible P. aeruginosa 10 [60]
Resistant P. aeruginosa 10
Cao et al. (2004) Retrospective
Observational
Tertiary;
China
Genitourinary,
respiratory
wound, blood,
tissue
Culture positive results for susceptible or MDR P. aeruginosa (when the
absence of susceptibility to three or more antibiotics: ceftazidime, cefepime,
piperacillin, ciprofloxacin, gentamicin, and imipenem or meropenem)
MDR P. aeruginosa 44 [57]
Susceptible P. aeruginosa 68
Eagye et al. (2009) Retrospective
Observational
Tertiary;
USA
Genitourinary,
respiratory,
wound
Culture positive results for meropenem susceptible or resistant P. aeruginosa;
control patients were located in the same unit and on the same day as cases
and without 105 DRG codes related to infection
Meropenem resistant P. aeruginosa 58 [53]
Susceptible P. aeruginosa 125
Control 57
Evans et al. (2007) Retrospective
Observational
Tertiary;
USA
Genitourinary,
respiratory,
wound
Culture positive results for susceptible or resistant P. aeruginosa; resistance
defined as resistance to all the drugs in one or more of the following
antibiotic classes: aminoglycosides, cephalosporins, carbapenems, and
fluoroquinolones.
Susceptible P. aeruginosa 73 [71]
Resistant P. aeruginosa 47
Furtado et al.
(2009)
Retrospective
Observational
ICU;
Brazil
Genitourinary,
respiratory,
wound
Culture positive results for imipenem susceptible or resistant P. aeruginosa;
control patients were hospitalized in the same ICU unit as the case
participants and matched by time (within a 30-day interval), age (within a
10-year interval), and time at risk (control patients were imipenem susceptible)
Imipenem resistant P. aeruginosa 63 [62]
Control 182
Furtado et al.
(2011)
Prospective
Observational
Tertiary;
Brazil
Respiratory Culture positive results for imipenem susceptible or resistant P. aeruginosa;
Isolates were screened for the presence of metallo-β-lactamases by using
multiplex PCR.
São Paulo Metallo-β-lactamase
(SPM-1) producing imipenem
resistant P. aeruginosa
5 [68]
Non-SPM-1-producing
susceptible P. aeruginosa
24
Gasink et al. (2006) Retrospective
Observational
Tertiary;
USA
Respiratory,
wound
Culture positive results for fluoroquinolone susceptible or resistant P. aeruginosa Fluoroquinolone resistant P.
aeruginosa
320 [64]
Susceptible P. aeruginosa 527
Hirakata et al.
(2003)
Retrospective
Observational
Tertiary;
Japan
Genitourinary,
respiratory,
wound
Culture positive results for blaIMP-positive or negative P. aeruginosa; control
subjects selected at random from among inpatients; control subjects samples
were blaIMP-negative P. aeruginosa
blaIMP-positive P. aeruginosa 69 [69]
blaIMP-negative P. aeruginosa 247
Kaminski et al.
(2011)
Nested case
cohort
ICU;
France
Respiratory Culture positive results for Ureido/carboxypenicillin susceptible or resistant
P. aeruginosa
Ureido/carboxypenicillin-
resistant P. aeruginosa
70 [66]
Susceptible P. aeruginosa 153
Lambert et al.
(2011)
Prospective
Observational
ICU; EU Respiratory Susceptibility testing in different centers was done according to local policies Ceftazidime resistant P. aeruginosa 366 [31]
Susceptible P. aeruginosa 1266
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Table 2 Description of studies included in systematic review (Continued)
Lautenbach et al.
(2010)
Retrospective
Observational
Tertiary;
USA
Genitourinary,
respiratory
wound, blood,
tissue
Culture positive results for imipenem susceptible or resistant P. aeruginosa Imipenem resistant P. aeruginosa 253 [63]
Susceptible P. aeruginosa 2289
Montero et al.
(2009)
Retrospective
Observational
Tertiary;
Spain
Respiratory Culture positive results for P. aeruginosa; MDR when the absence of
susceptibility to three or more antibiotic families (betalactams, quinolones,
carbapenems, and aminoglycosides); control patients also had nosocomial
infection (20% with P. aeruginosa), but were not multidrug-resistant
MDR P. aeruginosa 50 [58]
Control 50
Morales et al.
(2012)
Retrospective
Observational
Tertiary;
Spain
Genitourinary,
respiratory,
wound
Culture positive results for susceptible or resistant P. aeruginosa; MDR when
strains were resistant to carbapenems, β-lactams, quinolones, tobramycin, and
gentamicin
MDR P. aeruginosa 134 [49]
Resistant P. aeruginosa 119
Susceptible P. aeruginosa 149
Paramythiotou
et al. (2004)
Retrospective
Observational
(matched)
ICU;
France
Genitourinary,
respiratory,
wound
Culture positive results for susceptible or resistant P. aeruginosa; MDR were
resistant to piperacillin, ceftazidime, imipenem, and ciprofloxacin; control
patient was hospitalized in the same ICU as the corresponding case participant
during the study period but whose microbiological cultures for P. aeruginosa
showed no growth at any time during their ICU stay. Controls matched to
cases for length of ICU stay.
MDR P. aeruginosa 37 [54]
Control 34
Peña et al. (2013) Retrospective
Observational
Tertiary;
Spain
Respiratory MDR defined as strains non-susceptible to > = 1 agent in > = 3
anti-pseudomonal antimicrobial categories (carbapenems, β-lactams,
quinolones, tobramycin, and gentamicin)
MDR P. aeruginosa 27 [56]
Susceptible P. aeruginosa 56
Scheetz et al.
(2006)
Retrospective
Observational
Tertiary;
USA
Blood Culture positive results for fluoroquinolone susceptible or resistant P.
aeruginosa
Fluoroquinolone resistant P.
aeruginosa
79 [65]
Fluoroquinolone susceptible P.
aeruginosa
136
Söderström et al.
(2009)
Retrospective
Observational
(matched)
Tertiary;
Finland
Wound Culture positive results for resistant P. aeruginosa to ciprofloxacin, tobramycin,
and a combination of piperacillin and tazobactam; A control participant with
negative MDR P. aeruginosa culture was matched to each study participant
(a drug-sensitive strain of P. aeruginosa was cultured from 31 control
participants (48%))
MDR P. aeruginosa 64 [59]
Control 64
Tam et al. (2009) Retrospective
Observational
Tertiary;
USA
Blood Culture positive results for AmpC++ by ceftazidime susceptibility with and
without clavulanic acid
AmpC++ P. aeruginosa 21 [72]
Wild-type P. aeruginosa 33
Tam et al. (2010) Retrospective
Observational
Tertiary;
USA
Blood MDR was defined as culture positive results for resistance to three or more of
the following four classes of agents: antipseudomonal carbapenems,
antipseudomonal β-lactams (penicillins and cephalosporins), aminoglycosides,
and fluoroquinolones
MDR P. aeruginosa 25 [13]
Susceptible P. aeruginosa 84
Trouillet et al.
(2002)
Prospective
Observational
ICU;
France
Respiratory Culture positive results for piperacillin susceptible or resistant P. aeruginosa Piperacillin resistant P. aeruginosa 34 [67]
Piperacillin susceptible P.
aeruginosa
101
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Table 2 Description of studies included in systematic review (Continued)
Tumbarello et al.
(2013)
Retrospective
Observational
ICU; Italy Respiratory Culture positive results for piperacillin susceptible or resistant P. aeruginosa;
MDR if in vitro resistance to >1 antipseudomonal agent in 3 or more of the
following categories: β-lactam/β-lactamase inhibitors, cephalosporins,
carbapenems, quinolones and aminoglycosides
MDR P. aeruginosa 42 [55]
Non-MDR P. aeruginosa 68
Zavascki et al.
(2006)
Prospective
Observational
Tertiary;
Brazil
Blood,
genitourinary,
respiratory,
wound
Culture positive results for metallo-β-lactamase (MBL) –carrying versus
non-MBL- carrying P. aeruginosa
MBL-carrying P. aeruginosa 86 [70]
Non-MBL-carrying P. aeruginosa 212
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http://www.aricjournal.com/content/3/1/32also conducted a meta-analysis of all-cause mortality to
quantify the impact of resistant and MDR P. aeruginosa
on this clinical outcome.Methods
The authors followed standard systematic review methods
[43]. A systematic search was conducted in the Cochrane
Library and MEDLINE. In addition, the authors manually
reviewed citations from retrieved articles to ensure inclusion
of all relevant literature. Appendix 1 lists the initial search
strategy terms related to the pathogen (P. aeruginosa), mode
of infection (nosocomial, hospital-acquired, healthcare-
acquired, hospital-associated, healthcare-associated, and
ventilator-associated), and outcomes (resource utilization
including length of stay, antibiotic use/duration, proce-
dures, inpatient costs, readmission, recurrence, and death).
Study inclusion criteria included: article published in
English language; publication date between January 1, 2000
and February 28, 2013; sample size of at least 20 patients;
and adult hospitalized population. Articles published
before 2000 were not included to ensure that the analysis
focused on contemporary literature that reflects current
infection rates, resistance patterns, and clinical practice
guidelines. Exclusion criteria were applied to identify spe-
cial patient population subsets in which study results
would not provide data applicable to the general popula-
tion. Studies were not limited by the source of infection, and
all infection types were included as long as resistance was
present (see Table 2 for a summary of sources of infection).Figure 1 Literature review study flow diagram.Unpublished gray literature was not included and no
authors were directly contacted for unpublished data.
Two researchers with training in evidence-based methods
extracted relevant data for analysis. The extracted data
included study design; participant characteristics; follow-up
period; method of assessing resistant P. aeruginosa; associ-
ation between resistance status and outcome; potential
confounding variables adjusted for; method of ascertaining
outcome; and statistical analyses. A web-based, automated
data platform (Doctor Evidence, Santa Monica, CA) further
cross-calculated the data to identify any numerical discrep-
ancies (i.e., mismatches of sub-data to main population
data, data reported in percentiles conflicting with unit data
and vice versa). A third evidence-based review produced
the final digital data repository. The web-based platform
assessed identified studies for inclusion. Meta-analysis was
conducted using the random effects method of weighting
data for pooling [44]. The results are reported as summary
relative risk (RR).
We considered the following outcomes for inclusion
in a meta-analysis: all-cause mortality in hospital, length
of stay (hospital and ICU), hospital costs or charges,
microbiological infection clearance and readmissions.
The random effects meta-analyses assessed any potential
differential impact of resistant and MDR pathogens on the
outcomes of interest using unadjusted and adjusted data,
when available. All presented p-values were obtained from
analysis within included studies. The Cochrane Q Chi-
square test was used to test for heterogeneity of results
across studies and quantified with I2 [45]. In addition, we
Table 3 Studies describing in-hospital mortality in patients with resistant and multidrug-resistant Pseudomonas
aeruginosa infections
Setting Author Study groups (n) In-Hospital
Mortality
Reported
P-value
Ref
Tertiary care
center
Akhabue et al. (2011) Cefepime resistant P. aeruginosa (213) 20% 0.007 [61]
Susceptible P. aeruginosa (2316) 13%
Brooklyn Antibiotic Resistance Task Force
(2002)
Carbapenem resistant P. aeruginosa (10) 20% > 0.05
(NS)
[60]
Susceptible P. aeruginosa (10) 10%
Cao et al. (2004) MDR P. aeruginosad (44) 55% 0.05 [57]
Susceptible P. aeruginosa (68) 16%
Eagye et al. (2009) Meropenem resistant P. aeruginosa (58) 31% 0.152a [53]
Meropenem susceptible P. aeruginosa (125) 15%
Meropenem resistant P. aeruginosa (58) 31% 0.01a
Control (57) 9%
Evans et al. (2007) Resistant P. aeruginosae (47) 15% 0.43 [71]
Susceptible P. aeruginosa (73) 21%
Furtado et al. (2011) SPM-1-producing imipenem resistant P.
aeruginosa (5)
60% 0.59 [68]
Non-SPM-1-producing susceptible P. aeruginosa
(24)
75%
Gasink et al. (2006) Fluoroquinolone resistant P. aeruginosa (320) 24% 0.004 [64]
Fluoroquinolone susceptible P. aeruginosa (527) 16%
Hirakata et al. (2003) blaIMP-positive P. aeruginosa (69) 30.4% 0.41 [69]
blaIMP-negative P. aeruginosa (247) 25.5%
Lautenbach et al. (2010) Imipenem resistant P. aeruginosa (253) 17% 0.01 [63]
Imipenem susceptible P. aeruginosa (2289) 13%
Morales et al. (2012) MDR P. aeruginosaf (134) 25% < 0.05 [49]
Susceptible P. aeruginosa (149) 13%
Resistant P. aeruginosa (119) 22% <0.05
Susceptible P. aeruginosa (149) 13%
Peña et al. (2013) Non-MDR P. aeruginosa (27) 55% 0.33 [56]
MDR P. aeruginosag (56) 50%
Scheetz et al. (2006) Fluoroquinolone resistant P. aeruginosa (79) 32% 0.731 [65]
Fluoroquinolone susceptible P. aeruginosa (136) 29%
Tam et al. (2010) MDR P. aeruginosah (25) 56% 0.001 [13]
Susceptible P. aeruginosa (84) 17%
Zavascki et al. (2006) MBL-carrying P. aeruginosa (86) 51.2% 0.003 [70]
Non-MBL-carrying P. aeruginosa (212) 32.1%
ICU Lambert et al. (2011) Ceftazidime resistant P. aeruginosa (362)b 43% NR [31]
Susceptible P. aeruginosa (1251)b 37%
Ceftazidime resistant P. aeruginosa (82)c 41%
Susceptible P. aeruginosa (280)c 39%
Furtado et al. (2009) Imipenem resistant P. aeruginosa (63) 49% 0.02 [62]
Control (182) 34%
Kaminski et al. (2011) Ureido/carboxypenicillin resistant P. aeruginosa
(70)
43% 0.56 [66]
Ureido/carboxypenicillin susceptible P.
aeruginosa (153)
44%
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Table 3 Studies describing in-hospital mortality in patients with resistant and multidrug-resistant Pseudomonas
aeruginosa infections (Continued)
Paramythiotou et al. (2004) MDR P. aeruginosai (34) 47% 0.8 [54]
Control (34) 50%
Trouillet et al. (2002) Piperacillin resistant P. aeruginosa (34) 59% > 0.05
(NS)
[67]
Piperacillin susceptible P. aeruginosa (101) 50%
Tumbarello et al. 2013 MDR P. aeruginosaj (42) 60% 0.01 [55]
Susceptible P. aeruginosa (68) 35%
aAdjusted for time at risk; bPatients with pneumonia; cPatients with bloodstream infections; dAbsence of susceptibility to three or more antibiotics: ceftazidime,
cefepime, piperacillin, ciprofloxacin, gentamicin, and imipenem or meropenem; eAbsence of susceptibility to all the drugs in one or more of the following
antibiotic classes: aminoglycosides, cephalosporins, carbapenems, and fluoroquinolones; fAbsence of susceptibility to carbapenems, β-lactams, quinolones,
tobramycin, and gentamicin; gAbsence of susceptibility to one or more agent in three or more anti-pseudomonal antimicrobial categories (carbapenems,
β-lactams, quinolones, tobramycin, and gentamicin); hAbsence of susceptibility to three or more of the following four classes of agents: antipseudomonal carbapenems,
antipseudomonal β-lactams (penicillins and cephalosporins), aminoglycosides, and fluoroquinolones; iAbsence of susceptibility to piperacillin, ceftazidime, imipenem,
and ciprofloxacin; jAbsence of susceptibility to one or more antipseudomonal agent in 3 or more of the following categories: β-lactam/β-lactamase inhibitors,
cephalosporins, carbapenems, quinolones and aminoglycosides.
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proportions and calculated their confidence interval (CI)
and then back transformed the combined value. For meta-
analyses with at least 10 studies, we evaluated the poten-
tial for publication bias with funnel plots and Egger’s tests
for small study effects [46]. We looked for differences
across studies using stratified analyses to explain heterogen-
eity in association results. To assess study quality, we ap-
plied quality questions from the Newcastle-Ottawa Quality
Assessment Scales for case–control and observational
studies [47]. When feasible, sensitivity analyses were con-
ducted by excluding studies of high risk of bias. All ana-
lyses were performed in Stata version 13 (StataCorp,
College Station, Texas).
Studies that used hospital costs or charges as a defined
primary or secondary endpoint were included in thisFigure 2 A forest plot of unadjusted in-hospital all-cause mortality compa
Pneumonia. HABI = Health-acquired Blood Infection.analysis. Hospital costs and charges were inflated to
2012 US dollars using the Consumer Price Index (CPI)
as reported by the Bureau of Labor Statistics [48]. In one
study where the costs were reported in Euros [49], con-
version to USD was performed according the exchange
rate at the time of the original analysis.
This review was based on evaluation of data from pub-
lished studies and was exempt from ethics committee
approval. In addition, this review did not involve any direct
research on patients, and no informed consent was required.
Results and discussion
Study characteristics
Our literature search identified 1,970 potentially relevant
references (1,967 references and three full-text articles
identified through manual searching), which containedring resistant and susceptible P. aeruginosa. HAP = Health-acquired
Figure 3 A forest plot of adjusted in-hospital all-cause mortality comparing resistant and susceptible P. aeruginosa. HAP = Health-acquired
Pneumonia. HABI = Health-acquired Blood Infection.
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http://www.aricjournal.com/content/3/1/32terms from the search strategy listed (Appendix 1). Based
on review of abstracts only, 73 full text articles met the
necessary inclusion criteria previously mentioned. After
review of full text, an additional 50 articles were excluded
based on the same criteria (Figure 1).
Table 2 summarizes the definitions of controls, suscepti-
bility, resistance, and MDR used in the studies included in
the systematic review. Of note, consistent with other re-
ports, we found that the definition of resistance and MDR
in P. aeruginosa infections was inconsistent [50-52]. Resist-
ance was either based on a class of antimicrobials or to a
specific agent. Similarly, the most common definition for
MDR was laboratory-confirmed resistance to more thanFigure 4 Funnel plot with pseudo 95% confidence limits.one agent in three or more of categories of antibiotics,
though one study required evidence of resistance to five
different agents [49].
Of the 23 studies that met inclusion criteria, two were
prospective observational studies, 18 were retrospective
(Table 2). Of the 20 studies reporting on hospitalized
patients, six specifically studied ICU patients. The 23
studies represented a total of 10,570 patients, of which
7,881 had susceptible P. aeruginosa infections, 1,653
had resistant P. aeruginosa infections, 559 had MDR P.
aeruginosa infections, and 387 were control patients
defined as non-infected patients without P. aeruginosa
infections. Of the 23 studies, 2 were rated as good
quality (low risk of bias), 17 were of moderate quality
(medium risk of bias) and 4 were of poor quality (high
risk of bias) (Additional file 1). Most studies included a
mixture of patients with genitourinary, respiratory,
wound, and bloodstream as the source of infection.
The most common definition (43.5% of studies) for
MDR was laboratory-confirmed resistance to more than
one agent in three or more of categories of antibiotics
[13,17,49,53-59]. Resistance (non-MDR) was defined as
laboratory confirmed resistance to one particular anti-
biotic agent. Analysis of resistance included one study on
carbapenem-resistant P. aeruginosa (n = 10) [60], one study
on cefepime-resistant P. aeruginosa (n = 213) [61], one
study on meropenem-resistant P. aeruginosa (n = 58) [53],
two studies on imipenem-resistant P. aeruginosa (n = 316)
[62,63], two studies on fluoroquinolone-resistant P.
Table 4 Studies describing in-hospital mortality in patients with resistant and multidrug-resistant Pseudomonas
aeruginosa infections – cause of death identified specifically as Pseudomonas aeruginosa infection
Setting Author Study groups (n) Infection-related In-Hospital Mortality P-value Ref
Tertiary Care Center Cao et al MDR P. aeruginosaa (44) 45.5% <0.05 [57]
Susceptible P. aeruginosa (68) 7.4%
Hirakata et al blaIMP-positive P. aeruginosa (69) 5.8% 0.02 [69]
blaIMP-negative P. aeruginosa (247) 1.2%
Tam et al MDR P. aeruginosab (25) 52% <0.001 [13]
Susceptible P. aeruginosa (84) 9.5%
aAbsence of susceptibility to three or more antibiotics: ceftazidime, cefepime, piperacillin, ciprofloxacin, gentamicin, and imipenem or meropenem; bAbsence of
susceptibility to three or more of the following four classes of agents: antipseudomonal carbapenems, antipseudomonal β-lactams (penicillins and cephalosporins),
aminoglycosides, and fluoroquinolones.
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resistant P. aeruginosa (n = 366) [31], one study on ureido/
carboxypenicillin-resistant P. aeruginosa (n = 70) [66] and
one study on piperacillin-resistant P. aeruginosa (n = 34)
[67] and three studies on metallo-β-lactamase-carrying
P. aeruginosa (MBL-PA)[68-70]. Three studies included
resistant P. aeruginosa patients but did not define
resistance specific to any one treatment (n = 187) [49,71,72].
Three studies reported long-term clinical outcomes in
patients with MDR P. aeruginosa, but did not provide
data regarding in-hospital outcomes and therefore, were
excluded from meta-analysis [58,59,72].
Of the seven outcomes examined, in-hospital all-cause
mortality was the only endpoint for which a meta-analysis
was feasible; when only ICU mortality was reported, those
data were included in the analysis of in-hospital mortality.
For the other six outcomes, a meta-analysis was not
possible due to insufficient data or heterogeneity of data. For
the all-cause mortality analysis, we were unable to stratify by
the type of infection owing to the small sample size.Mortality outcomes
Twenty studies reported data on hospital all-cause mor-
tality (Table 3). In-hospital all-cause mortality ranged
from 25 to 60% in the MDR P. aeruginosa group, 15 to
59% in the resistant P. aeruginosa group, and 7 to 50%
in the susceptible P. aeruginosa group. Mortality was 34%
(95% confidence interval (CI) 27% – 41%) in patients with
resistant and MDR P. aeruginosa compared to 22% (95%
CI 14% – 29%) with susceptible P. aeruginosa. When
comparing patients with resistant P. aeruginosa infections
versus those with susceptible P. aeruginosa infections,
resistance was associated with 24% higher risk of in-hospital
all-cause mortality (11 studies, 9,082 participants unadjusted
RR 1.24, 95% CI 1.11 – 1.38; I2 24.6%). Comparing patients
with MDR P. aeruginosa infections with patients with sus-
ceptible P. aeruginosa infections (5 studies, 697 participants),
the MDR P. aeruginosa group had a greater than 2-fold
increase in risk of in-hospital all-cause mortality (unadjusted
RR 2.34, 95% CI 1.53 – 3.57; I2 78.8%).We conducted a meta-analysis of 18 studies containing
20 comparisons (10,422 participants) that reported in-
hospital all-cause mortality in patients with any resistant
P. aeruginosa versus susceptible P. aeruginosa infections.
The two additional comparisons came from one study that
contributed data for both resistant and MDR P. aeruginosa
groups [49] and another study that contained two differ-
ent infection-site comparisons [63]. Using data reported
from 18 studies, the meta-analysis demonstrated an in-
creased risk of mortality with any resistant P. aeruginosa
(unadjusted (RR) 1.53, 95% CI 1.28 – 1.82, I2 73.1%),
compared to susceptible P. aeruginosa (Figure 2).
Only seven studies reported data for an adjusted meta-
analysis (Additional file 2: Table S1); adjusted data from
these studies demonstrated an increased risk of mortality
(adjusted RR 1.24, 95% CI 0.98 – 1.57, I2 57.5%) that did
not reach statistical significance probably due to the small
sample size (Figure 3). We were unable to perform compar-
isons against control patients without P. aeruginosa infec-
tions due to a scarcity of studies reporting mortality end
points in this group of patients [55,62]).
For both unadjusted and adjusted data, stratified meta-
analyses by study-level characteristics identified studies with
prospective follow-up or those conducted at multi-center or
ICU as less heterogeneous (Additional file 2: Table S2-S3);
however, excluding high risk of bias studies did not change
the overall estimate or measures of consistency (I2).
Funnel plots of all studies reporting unadjusted mortality
(Figure 4) indicate a potential for missing studies with
inverse associations (RR <1.0). Since <10 studies reported
adjusted mortality data, we did not assess publication bias
for this analysis.
Across three studies that reported infection-related
mortality, all found a statistically significantly increased
risk in patients with MDR P. aeruginosa compared to
those with susceptible P. aeruginosa (Table 4).
Economic outcomes
Ten studies containing 12 comparisons reported hospital
length of stay (Table 5). Definitions and measures for
length of stay varied across eligible studies making direct
Table 5 Studies describing hospital length of stay in patients with resistant and multidrug-resistant Pseudomonas
aeruginosa infections
Author Study groups (n) Median (mean) Hospital Length of
Stay (days)
Reported
Significance
(p-value or
95% CI)
Ref
Main findings
Brooklyn Antibiotic Resistance Task
Force (2002)*
Carbapenem susceptible P. aeruginosa (10) 20 (17) 0.002 (0.001) [60]
Carbapenem resistant P. aeruginosa (10) 33.5 (36)
Eagye et al. (2009)* Meropenem resistant P. aeruginosa (58) 30 <0.001 [53]
Meropenem susceptible P. aeruginosa (125) 16
Meropenem resistant P. aeruginosa (58) 30 <0.001
Control (57) 10
Evans et al. (2007)‡ Susceptible P. aeruginosa (73) 20 0.03 [71]
Resistant P. aeruginosae (47) 26
Furtado et al. (2009)‡ Imipenem resistant P. aeruginosa (63) 25 0.006 [62]
Control (182) 15
Gasink et al. (2006)* Fluoroquinolone resistant P. aeruginosa (320) 10 0.13 [64]
Fluoroquinolone susceptible P. aeruginosa
(527)
9
Kaminski et al. (2011)† Ureido/carboxypenicillin resistant P.
aeruginosa (70)
50 0.24 [66]
Ureido/carboxypenicillin susceptible P.
aeruginosa (153)
47.5
Lautenbach et al. (2010)† Imipenem resistant P. aeruginosa (253) 16 <0.001 [63]
Imipenem susceptible P. aeruginosa (2289) 9
Morales et al. (2012)‡ MDR P. aeruginosaf (134) 39 (45.7) <0.001a [49]
Susceptible P. aeruginosa (149) 20 (25.1)
Resistant P. aeruginosa (119) 30 (39.0) <0.001a
Susceptible P. aeruginosa (149) 20 (25.1)
Paramythiotou et al. (2004)† MDR P. aeruginosag (34) 44.5 (57.0)b,d/11.1c,d 0.28/0.81 [54]
Control (34) 43.5 (46.9)b,d/5.8c,d
Tam et al. (2010)† MDR P. aeruginosah (25) 26.4c 0.12 [13]
Susceptible P. aeruginosa (84) 16.5c
*Length of stay reported after identification of infection with P. aeruginosa; †Length of stay reported as total length of stay; ‡Length of stay not defined as total
length of stay or length of stay after identification of infection with P. aeruginosa; a P-value reported for mean length of stay; b Length of ICU stay (ICU stay
matched between cases and controls); cLength of stay in hospital following ICU discharge; dStudy reported mean length of stay; eAbsence of susceptibility to all
the drugs in one or more of the following antibiotic classes: aminoglycosides, cephalosporins, carbapenems, and fluoroquinolones; fAbsence of susceptibility to
carbapenems, β-lactams, quinolones, tobramycin, and gentamicin; g Absence of susceptibility to piperacillin, ceftazidime, imipenem, and ciprofloxacin; hAbsence of
susceptibility to three or more of the following four classes of agents: antipseudomonal carbapenems, antipseudomonal β-lactams (penicillins and cephalosporins),
aminoglycosides, and fluoroquinolones.
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et. al. was a case control study that matched MDR P.
aeruginosa cases and controls (defined as patients with-
out P. aeruginosa infections) on the basis of median
length of stay in the ICU (45 versus 44 days). Therefore,
we did not include these control patients in analyses of
comparative ICU length of stay. Of note, this study
reported hospital stay following ICU discharge of
11.1 days (standard deviation [SD] of 18.6) in the MDR
P. aeruginosa group and 5.8 days (SD 10.4) in the
control group (p = 0.28) [54].Two studies reported mean hospital length of stay
among patients with MDR P. aeruginosa; one study
reported total length of stay (46 days, SD 29) [49] and the
other reported mean length of hospital stay associated
with bacteremia (26.4 days; SD 28.3) [13]. Among patients
with resistant P. aeruginosa, 8 studies reported median
hospital length of stay in patients with bacteremia ran-
ging from 10 to 50 days [13,49,53,54,60,62-64,66,71];
and 6 studies reported median hospital length of stay in
susceptible P. aeruginosa infections ranging from 9 to
48 days [13,49,53,60,63,64,66,71]. Two studies reported
Table 6 Studies describing intensive care unit length of stay in patients with resistant and multidrug-resistant
Pseudomonas aeruginosa infections
Author Study groups (n) Median ICU Length of Stay (days) Reported
Significance
(p-value or
95% CI)
Ref
Main findings
Evans et al. (2007) Susceptible P. aeruginosa (73) 6 0.02 [71]
Resistant P. aeruginosac (47) 13
Kaminski et al. (2011) Ureido/carboxypenicillin resistant P. aeruginosa (70) 29 0.37 [66]
Ureido/carboxypenicillin susceptible P. aeruginosa (153) 28.5
Paramythiotou et al. (2004) MDR P. aeruginosad (34) 44.5 (57.0)a,b 0.55 [54]
Control (34) 43.5 (46.9)a,b
a Length of ICU stay (ICU stay matched between cases and controls); b Study reported mean length of stay; c Absence of susceptibility to all the drugs in one or
more of the following antibiotic classes: aminoglycosides, cephalosporins, carbapenems, and fluoroquinolones; d Absence of susceptibility to piperacillin,
ceftazidime, imipenem, and ciprofloxacin.
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15 days, respectively) [53,54,62].
Three studies examined length of stay in the ICU
(Table 6). One study reported mean ICU length of stay of
47 days in patients with MDR P. aeruginosa [54]. As
described previously, the control group in the analysis by
Paramythiotou et. al. [54] matched control patients with
cases on the basis of ICU length of stay and therefore weTable 7 Studies describing hospital costs or charges in patien
aeruginosa infections
Author Study groups (n) Descripti
Eagye et al. (2009) Meropenem resistant P. aeruginosa
(58)
Median tot
Meropenem susceptible P.
aeruginosa (125)
Meropenem resistant P. aeruginosa
(58)
Control (57)
Evans et al. (2007) Susceptible P. aeruginosa (73) Median tot
Resistant P. aeruginosaa (47)
Gasink et al.
(2006)
Fluoroquinolone resistant P.
aeruginosa (320)
Median total
Fluoroquinolone susceptible P.
aeruginosa (527)
Lautenbach et al.
(2010)
Imipenem resistant P. aeruginosa
(253)
Mean hospital c
sampling
Imipenem susceptible P. aeruginosa
(2289)
Morales et al.
(2012)
MDR P. aeruginosab (134) Mean hospital c
sampling
Susceptible P. aeruginosa (149)
Resistant P. aeruginosa (119)
Susceptible P. aeruginosa (149)
*Hospital charges reported after identification of infection with P. aeruginosa; †P-va
in one or more of the following antibiotic classes: aminoglycosides, cephalosporins,
β-lactams, quinolones, tobramycin, and gentamicin.did not include this control group. Two studies reported
median ICU length of stay of 13 days (interquartile range
2–36) versus 6 days (interquartile range 0–16) in one
study [66,71] and was similar in both groups in the other
study (29 days) [66,71].
Five studies reported outcomes related to hospital costs
(Table 7). Four of five studies reported inpatient care costs.
Of the four studies that reported inpatient care costs, twots with resistant and multidrug-resistant Pseudomonas
on of cost Hospital Inpatient Care Costs
or Charges
Reported
P-value
Ref
Main findings
al cost (IQR) $100,704 ($27,710 – $183,125) < 0.001 [53]
$32,594 ($13,112 – $100,702)
$100,704 ($27,710 – $183,125) < 0.001
$25,744 ($17,456 – $40,616)
al cost (IQR) $99,672 ($43,714 – $187,260 0.015 [71]
$69,502 ($24,853 – $113,933)
charges (IQR)* $62,325 ($22,129 - $188,979) 0.008 [64]
$48,733 ($18,760 - $124,820)
ost after culture
(95% CI)
$286,417 ($234,326 – $338,510) < 0.001 [63]
$189,274 ($172,428 – $206,121)
ost after culture
(median)
$13,178 ($5,745) < 0.001† [49]
$4,258 ($2,420)
$10,662 ($5,248) < 0.001†
$4,258 ($2,420)
lue reported for mean length of stay; aAbsence of susceptibility to all the drugs
carbapenems, and fluoroquinolones; bAbsence of susceptibility to carbapenems,
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logical infection confirmation. One study reported hospital
charges incurred after microbiological infection confirm-
ation [64]. Additionally, one study reported costs from a
hospital in Spain [49] and therefore cannot be directly com-
pared to the remaining three studies that represent US
hospital setting costs. Studies also varied in the reporting of
mean versus median costs. For the two US studies that re-
ported median costs, costs were higher in the resistant
P. aeruginosa groups (median = $99,672, interquartile
range (IQR) = $43,714 - $187,260 [71]; median =
$100,704, IQR = $27,710 - $183,125 [53]) compared to
patients with susceptible P. aeruginosa infections (median =
$69,502, IQR = $24,853 - $113,933 [71]; median = $32,594,
IQR = $13,112 - $100,702 [53]) and control patients
(median = $25,744, IQR = $17,456 - $40,616 [71]).
Other outcomes
Need for mechanical ventilation was studied as an
index of patient outcomes in one case control study;
patients with MDR P. aeruginosa required more days of
mechanical ventilation than patients with susceptible P.
aeruginosa (15 versus 11 days) [55]. One study reported
persistence of microbiological infection of 75% and
clinical persistence or recurrence of 38% in patients
with MDR P. aeruginosa infection versus 61% and 39%
respectively, in the non-MDR P. aeruginosa group [56].
As noted in the Methods section, meta-analyses were
not performed for these outcomes due to insufficient
data and heterogeneity of the literature.
Conclusions
This systematic review of the literature identified some
strengths and weaknesses in relation to published data on
the impact of P. aeruginosa infections on clinical and eco-
nomic outcomes. The meta-analysis of studies examining
the impact of resistance or MDR infection indicates a sig-
nificant increase in hospital all-cause mortality compared to
infections due to susceptible pathogens. Patients with
resistant and MDR P. aeruginosa infections versus those
with susceptible P. aeruginosa infections had a relative risk
of 1.24 and 2.31, respectively.
In keeping with previous literature [27,28,32], our review
suggests that MDR and resistant P. aeruginosa infections
are associated with higher hospital and ICU length of stay
as an outcome compared to susceptible P. aeruginosa infec-
tions; however, there was a scarcity of studies examining
length of stay in patients with resistant P. aeruginosa in-
fections compared to control patients without infection.
Further research is needed into the economic impact of
resistant P. aeruginosa infections and future studies must
take into account regional and national differences in
standards of care, and other critical patient level factors
including community versus hospital acquired infection,duration of hospitalization prior to the infection, severity
of illness, the timeliness and appropriateness of therapy,
time at risk of infection, and site of infection [73].
Among reviewed studies, only one study highlighted
inadequate initial antibiotic therapy as a significant risk
factor for in-hospital mortality [55]. The importance of
appropriate treatment was recently confirmed in a study of
P. aeruginosa bloodstream infections; although neither
bloodstream infections with metallo-β-lactamase producing
P. aeruginosa nor bloodstream infections with various re-
sistance phenotypes of P. aeruginosa were independently
associated with mortality or length of hospital stay [74].
Inadequate initial therapy that does not provide coverage
for resistant P. aeruginosa is associated with poor clinical
outcomes, longer hospital stays and higher costs [37,75-78].
A prospective study examining patients with bloodstream
infections due to P. aeruginosa found that inappropriate
empirical antibiotic treatment was associated with a two-
fold increased risk of mortality [79]. A retrospective study
from a large tertiary hospital in the US also demonstrated
that inappropriate initial antimicrobial treatment was an
independent determinant of hospital mortality in patients
with P. aeruginosa bloodstream infections and was associ-
ated with a doubling in the odds ratio for death [40]. The
timing of initiation of therapy and site of infection were not
considered within the meta-analysis due to a lack of com-
parable data, but should be an area for further research.
Future analyses of the economic impact of resistance
should also consider use of propensity scoring to reduce
the impact of some these potential confounders [80].
This review and meta-analysis should be interpreted in
light of a few limitations. Our inclusion criteria required
that studies only consider nosocomial infection and were
published in English [28-30]. Additionally, studies that
were eligible for inclusion did not report on 30 day mor-
tality. Finally, the literature is heterogeneous with respect
to the definition of MDR and site of infection with P. aer-
uginosa. As a result, combined analysis may misrepresent
the true picture within different diseases (e.g. ventilator-
associated pneumonia versus complicated UTIs).
Confounding in observational studies reporting unadjusted
data should be acknowledged. For example, patients with re-
sistant P. aeruginosa represent a sicker population, who may
have been treated with more antibiotics and may have had a
longer length of stay. These factors may have influenced the
outcome of in-hospital mortality rather than resistant organ-
ism, specifically. The choice of the control group (e.g. pa-
tients with infection with susceptible strains versus patients
without any infection at all) may have also influenced the
results of the meta-analyses. The review findings indicate
that resistant P. aeruginosa can be a potential marker for
increased in-hospital mortality. Analyzing the impact of
resistance on length of stay and costs is difficult due to
competing events of mortality and discharge or time
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in most of the included studies. With P. aeruginosa, the
situation is further complicated by the emergence of
resistance during therapy [12].
From a societal and policy perspective, several sig-
nificant stakeholders who have a major role to play in
combating the burgeoning public health threat of anti-
microbial resistance include: legislators, regulatory author-
ities, payers, pharmaceutical companies, hospital systems
and physicians. Hospitals will need to initiate surveillance
programs, adopt progressive policies, and embrace anti-
biotic stewardship as not just a means to cut costs but
improve individual patient outcomes and provide societal
benefit. Payers will have to adopt policies that support use
of new, appropriate and/or effective antibiotics. Finally
physicians will need to develop and implement appropri-
ate infection control measures and generate evidence to
support clinical decision-making and enable a tailored
approach to treating infections.
In conclusion, the findings of this analysis underscore
the substantial clinical and economic costs associated with
resistant and, particularly, MDR P. aeruginosa in hospital-
ized patients. Decision-makers must prioritize implemen-
tation of best practices, treatment pathways and incentive
systems to improve outcomes in this patient population.
Novel and evolving treatment strategies, such as increas-
ing heterogeneity of antibiotics prescribing, should be
further explored as a valuable strategy for minimizing the
spread of resistance in P. aeruginosa in hospitals [81].
Additionally, this analysis emphasized the need to ensure
consistency in the definition of resistance to allow for add-
itional comparative analyses with outcomes other than
mortality in the future.
Appendix 1. Search strategy terms
The initial search strategy utilized was as follows: pseudo-
monas[tiab] AND (cross infection [82] OR nosocomial[tiab]
OR hospital-acquired[tiab] OR healthcare-acquired[tiab]
OR hospital-associated[tiab] OR healthcare-associated[tiab]
OR ventilator-associated[tiab] OR hospital[tiab] OR hospi-
tals[tiab] OR hospitalized[tiab] OR intensive care or critical
care) AND eng[la] AND (prevalence [82] OR prevalence
[tiab] OR rate[tiab] OR risk factors [82] OR mortality [82]
OR mortality[tiab] OR economics[mesh subheading] OR
economic[tiab] OR risk[tiab] OR “statistics and numerical
data”[mesh subheading] OR mortality[mesh subheading]
OR patterns[tiab] OR epidemiology[mesh subheading] OR
Surveillance[tiab] OR “risk factors” OR epidemiology OR
outcome* OR cost[tiab]) AND (resistant OR resistance
OR MDR[tiab] OR susceptib*[tiab] OR nonsusceptib*
[tiab]) NOT (pediatric OR child[tiab] OR children[tiab]
OR neonate*[tiab] OR neonatal[tiab] OR infant[tiab] OR
infants[tiab] OR inhalation[tiab] OR inhaled[tiab] OR
burn[tiab] OR transplant*[tiab] NOT (review [83] ORletter [83] OR case reports [83] OR meta-analysis [83] OR
editorial [83] OR comment [83]).
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